Reply to Alizazgar J. Dangers of the use of hydroxychloroquine and azithromycin combination in COVID-19 patients
- PMID: 33549822
- PMCID: PMC7862014
- DOI: 10.1016/j.tmaid.2021.101984
Reply to Alizazgar J. Dangers of the use of hydroxychloroquine and azithromycin combination in COVID-19 patients
Comment on
-
Dangers of the use of hydroxychloroquine and azithromycin combination in COVID-19 patients.Travel Med Infect Dis. 2020 Nov-Dec;38:101881. doi: 10.1016/j.tmaid.2020.101881. Epub 2020 Sep 18. Travel Med Infect Dis. 2020. PMID: 32956851 Free PMC article. No abstract available.
References
-
- The cardiotoxicity of antimalarials WHO evidence review group meeting. 13-14 October 2016. https://www.who.int/malaria/mpac/mpac-mar2017-erg-cardiotoxicity-report-... Varembé Conference Centre, Geneva, Switzerland.
-
- Strle F., Maraspin V. Is azithromycin treatment associated with prolongation of the Q-Tc interval? Wien Klin Wochenschr. 2002;114(10–11):396–399. - PubMed
-
- Fossa A.A., Wisialowski T., Duncan J.N., Deng S., Dunne M. Azithromycin/chloroquine combination does not increase cardiac instability despite an increase in monophasic action potential duration in the anesthetized Guinea pig. Am J Trop Med Hyg. 2007 Nov;77(5):929–938. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources